Synta Pharmaceuticals announced final results from the GALAXY-1 trial for ganetespib in patients with advanced non-small lung cancer (NSCLC) with adenocarcinoma histology most likely to benefit from second-line treatment. Ganetespib is a selective inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone which controls the folding and activation of a number of client proteins that drive tumor development and progression.
GALAXY-1 was a randomized, multi-center study designed to identify patient populations that are most responsive to treatment with the combination of ganetespib and docetaxel. Co-primary endpoints of the study were progression free survival (PFS) in patients with elevated LDH (eLDH) and PFS in patients with mutant KRAS (mKRAS).
Prespecified stratification factor analysis has shown that the chemosensitive patient population, the patients diagnosed with advanced NSCLC more than 6 months prior to study entry, derived the most benefit with combination treatment. This chemosensitive population was selected for the ongoing Phase 3 GALAXY-2 trial.
For more information call (781) 274-8200 or visit Syntapharma.com.
This article originally appeared on MPR